Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Plinabulin - BeyondSpring Pharmaceuticals

Next Previous
Drug Profile

Plinabulin - BeyondSpring Pharmaceuticals

Alternative Names: BPI 2358; NPI 2358

Latest Information Update: 04 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Nereus Pharmaceuticals
  • Developer BeyondSpring Pharmaceuticals; Big Ten Cancer Research Consortium; M. D. Anderson Cancer Center; Nereus Pharmaceuticals; Rutgers Cancer Institute of New Jersey
  • Class Antineoplastics; Imidazoles; Piperazines; Small molecules
  • Mechanism of Action Angiogenesis inhibitors; Antigen presenting cell stimulants; Guanine nucleotide exchange factor stimulants; Mitosis inhibitors; Tubulin polymerisation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preregistration Neutropenia
  • Phase III Non-small cell lung cancer
  • Phase II Small cell lung cancer
  • Phase I/II Cancer
  • No development reported Bladder cancer; Brain cancer; Breast cancer; Gastric cancer; Glioblastoma; Sickle cell anaemia; Soft tissue sarcoma; Solid tumours

Most Recent Events

  • 23 Apr 2026 Pharmacodynamic and adverse events data from a preclinical studies in Cancer released by BeyondSpring
  • 22 Apr 2026 (BeyondSpring Pharmaceuticals plans a phase III DUBLIN-4 trial for Non-small cell lung cancer (Combination therapy; Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV, Infusion) in June 2026 (NCT07361484)
  • 12 Dec 2025 Efficacy and adverse events data from the phase III DUBLIN-3 trial in Non-small cell lung cancer released by BeyondSpring Pharmaceuticals

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top